Eli Lilly News

From food safety fears, to perceived health benefits, or just the peace of knowing where their meals come from, more Hoosiers are turning to food grown and raised in the ways of generations past.

Eli Lilly & Co. : Jim Cramer ranked this stock a Buy . The stock closed at $40.53, its 52-week high is $42.03, and its 52-week low is $33.75. Oshkosh Corporation : Jim Cramer ranked this stock a Sell .

A study published in a British medical journal raises questions about the theory that raising HDL, or good cholesterol, can help to prevent heart disease.

Several studies have documented rates of statin prescription at discharge, in any dose, as a quality performance measure.

Eli Lilly, along with other Big Pharma names such as GlaxoSmithKline and Novartis , has been colluding with Indian drug regulators to speed up approval procedures and put drugs on the Indian market that are not yet available or even legal in other countries.

Billionaire activist investor Carl Icahn has made a fortune off of targeting declining biotech companies.

FORT WAYNE, Ind. - Six large Indiana-headquarted companies represented the state on the FORTUNE 500 list of America's largest corporations for 2012.

Two Cuban brothers were arrested and charged with helping steal about $80 million in pharmaceuticals, including Prozac and Zyprexa, from an Eli Lilly & Co.

Robbery suspects Suhong Wu and Ernesto Romero Vidal seen in image of the Connecticut Eli Lilly warehouse where $75 million in drugs were stolen.

A comparative lack of diversity in their offerings could pose higher earnings pressure to the 'pure' pharma players such as AstraZeneca , Bristol-Myers and Eli Lilly , over the next three years, reports Fitch, while firms that are more diversified, like Johnson & Johnson and Bayer , will be better situated in that regard.

A Vivus Inc. pill that is supposed to provide erections within 15 minutes, about half the time or less than Eli Lilly and Co.'s Cialis or Pfizer Inc.'s Viagra, has received U.S. regulatory approval.

30, 2012 Source: Eli Lilly news release To read entire report, click here. Eli Lilly and Company today announced financial results for the first quarter of 2012.

Apr 30 - Fitch Ratings says pharmaceuticals companies which focus on pure pharmaceuticals, such as AstraZeneca , Bristol Myers Squibb Company and Eli Lilly & Co.'s are likely to show the highest pressure on sales and EBITDA over the next three years compared to more diversified pharmaceuticals players, such as Johnson & Johnson or Bayer .